2-Phenyl-1H-inden-1,3(2H)-dion

Phenindione

HCID 4760

Grundinformationen

CAS
83-12-5
Standard-SMILES
O=C1c2ccccc2C(=O)C1c1ccccc1
InChIKey
NFBAXHOPROOJAW-UHFFFAOYSA-N
Summenformel
C15H10O2
Durchschnittliche Molmasse
222,24 g/mol
Monoisotopische Masse
222,06807956

Überblick

Phenindione is a beta-diketone and an aromatic ketone. It has a role as an anticoagulant. It derives from a hydride of an indane.

Namen und Bezeichner

Bevorzugter Name
Phenindione
IUPAC
2-phenylindene-1,3-dione
Lokaler Name
2-Phenyl-1H-inden-1,3(2H)-dion
Englischer Name
2-Phenyl-1,3-indandione
Summenformel
C15H10O2
Molmasse
222.24

Namen und Synonyme

phenindione83-12-52-Phenyl-1,3-indandione2-Phenyl-1H-indene-1,3(2H)-dioneRectadioneDaniloneDindevanHedulinDiophindaneAthrombonFenhydrenIndon
Weitere Namen anzeigen
PIDIndionMTA21H-Indene-1,3(2H)-dione, 2-phenyl-BindanIndema
PhenylindanedionePhenylindioneDanedionDiadilanEmandionePhenhydrenPhenillinTheradione

Datenbank-Bezeichner

CAS
83-12-5
PubChem CID
4760
DTXSID
DTXSID5023453
ChEMBL
CHEMBL711
ChEBI
CHEBI:8066
UNII
5M7Y6274ZE
EC Number
201-454-4
Nikkaji
J166.097G

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,9
Polarare Oberfläche (TPSA)
34,1 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
1
Schwere Atome
17

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
pH4.5 IN SATURATED SOLN @ 25 °C
SpringerMaterials PropertiesChemical shift
LogP2.6
OdorALMOST ODORLESS
Color/Form · 2 Einträge

LEAFLETS FROM ALCOHOL

CREAMY WHITE TO PALE YELLOW CRYSTALS OR CRYSTALLINE POWDER

Physikochemische Eigenschaften

Schmelzpunkt
144 · 144-148 °C(lit.)
Siedepunkt
243.3 °C · 243.3 °C (0.3 mmHg)
Dichte
1.1404 · 1.1404 (rough estimate)
Brechungsindex
1.66 · 1.6600 (estimate)
Flammpunkt
208 °C · 208 °C
storage temp.
Inert atmosphere,Room Temperature

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P272, P280, P301+P316, P302+P352, P321, P330, P333+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxikologische Informationen

Treatment · 1 Eintrag

The primary antidote to phenindione poisoning is immediate administration of vitamin K1 (initially slow intravenous injections of 10-25 mg repeated all 3-6 hours until normalisation of the prothrombin time; then 10 mg orally four times daily as a "maintenance dose"). It is an extremely effective antidote, provided the poisoning is caught before too much damage has been done to the victim's circulatory system. At high doses phenindione can affect the body for many months, and the antidote must be administered regularly for a long period of time. (L1257)

Interactions · 5 Einträge

HALOPERIDOL WAS FOUND TO REDUCE PROTHROMBIN TIME NORMALLY PRODUCED BY PHENINDIONE.

ACTIVITY OF...INDANDIONE ANTICOAGULANT PHENINDIONE HAVE ALSO BEEN ENHANCED BY C-17-ALKYLATED ANDROGENS.

CORTICOTROPIN & ADRENOCORTICOSTEROIDS HAVE BEEN REPORTED TO CAUSE SEVERE HEMORRHAGE WHEN GIVEN WITH ORAL ANTICOAGULANTS... /ANTICOAGULANTS/

ANTIPYRINE (IN VIVO) & SULFINPYRAZONE (IN VITRO) HAVE BEEN REPORTED TO INTERACT WITH WARFARIN & SHOULD BE USED CAUTIOUSLY IN PT RECEIVING ANTICOAGULANTS. /ANTICOAGULANTS/

For more Interactions (Complete) data for PHENINDIONE (12 total), please visit the HSDB record page.

Health EffectsPhenindione is an anticoagulant and may cause internal bleeding, leading to shock, loss of consciousness, and eventually death. (L1257)
Exposure RoutesIngestion (L1817) ; dermal (L1817). Absorbed slowly from the gastrointestinal tract.
Toxicity Summary · 1 Eintrag

Phenindione inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. (A308)

Signs and SymptomsPhenindione may cause bleeding complications. (L1257)

Sicherheitsdaten

wgk
3
ridadr
UN 2811 6.1/PG 3
hs_code
2914.39.9000
RTECS-Nr.
NK6125000
risk_code
25-43
hazard_code
T

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein Binding88%
Pharmacodynamics · 1 Eintrag

Phenindione thins the blood by antagonizing vitamin K which is required for the production of clotting factors in the liver. Anticoagulants such as Phenindione have no direct effect on an established thrombus, nor do they reverse ischemic tissue damage (damage caused by an inadequate blood supply to an organ or part of the body). However, once a thrombus has occurred, the goal of anticoagulant treatment is to prevent further extension of the formed clot and prevent secondary thromboembolic complications which may result in serious and possibly fatal sequelae. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higer incidence of severe adverse effects.

Mechanism of Action · 3 Einträge

Phenindione inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.

.../ANTICOAGULANTS/ BLOCK HEPATIC FORMATION OF FACTORS II, VII, IX, & X BY COMPETITIVELY INHIBITING ACTION OF VITAMIN K. ... COUMARIN ANTICOAGULANTS MAY ALSO AFFECT TRANSPORT OF VITAMIN K TO ITS SITE OF ACTION. /ANTICOAGULANTS/

ORAL ANTICOAGULANTS HAVE ONLY ONE MAJOR PHARMACOLOGICAL EFFECT--INHIBITION OF BLOOD-CLOTTING MECHANISMS BY INTERFERING WITH HEPATIC SYNTH OF VITAMIN K-DEPENDENT CLOTTING FACTORS. ...EXERT THEIR INITIAL EFFECT IN VIVO ONLY AFTER LATENT PERIOD... /ORAL ANTICOAGULANTS/

Biological Half-Life5-10 hours
Metabolism/Metabolites · 2 Einträge

Hepatic.

Hepatic. Half Life: 5-10 hours

Verwendung und Herstellung

Uses · 2 Einträge

MEDICATION

Phenindione is an anticoagulant drug derived from coumarin. (L1262) For the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. Also used for anticoagulant prophylaxis.

Methods of ManufacturingBY HEATING PHTHALIDE WITH BENZALDEHYDE AND SODIUM ETHYLATE SOLN: DIECKMANN, BER 47, 1439 (1914).
Formulations/Preparations...IS AVAIL FOR ORAL USE IN 20- & 50-MG TABLETS.
Use ClassificationPharmaceuticals
Anwendungen · 2 Einträge

BeschreibungPhenindione is an anticoagulant and vitamin K antagonist. It inhibits the reduction of vitamin K1 epoxide to vitamin K1 by vitamin K1 epoxide reductase in rat liver homogenates in a concentration-dependent manner. In vivo, phenindione (500 mg/kg) inhibits prothrombin synthesis and conversion of vitamin K1 epoxide to vitamin K1 in rats by 50 and 57%, respectively. Dietary administration of phenindione (4 mg/kg per day) inhibits aortic atherosclerosis or intracardial thrombosis in rat models of diet-induced atherosclerosis or intravascular thrombosis, respectively.

VerwendenOral anticoagulant (indanedione).

Anbieter77 Anbieter

北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
成都彼样生物科技有限公司18108052721 · [email protected]

Zugehörige Reaktionen

1

Notizen zur Verbindung

Wird geladen…